Latest / The Well-Built Life / Unlocking Cancer’s Sugar Shield: AbLec’s Promise in Immunotherapy
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Rachel, well, Thomas... It's interesting how
- 0:27Speaker 1: much cancer has evolved to outsmart the immune system. Take
- 0:31Speaker 1: glycan modifications, for instance. They are effectively this sugar shield
- 0:35Speaker 1: that cancer cells use to deflect immune attacks.
- 0:38Speaker 2: Thomas. Exactly, Rachel. It's fascinating how that sugar shield can
- 0:42Speaker 2: mask cancer cells from the immune system. Let's step back
- 0:46Speaker 2: and look at a more granular example. Cancer cells express
- 0:49Speaker 2: high levels of sialic acids on their surface, which act
- 0:52Speaker 2: like molecular breaks for immune cells. Right.
- 0:55Speaker 1: So the sialic acids bind to siglec receptors. These are
- 0:59Speaker 1: essentially brake pedals for immune cells. When those brakes are engaged,
- 1:04Speaker 1: the immune response is dampened, allowing cancer cells to proliferate unchecked.
- 1:08Speaker 2: Precisely. And this brings us to a crucial point. The
- 1:12Speaker 2: research by Carolyn Bertazzi and her team at Stanford and MIT,
- 1:16Speaker 2: published in Nature Biotechnology in 2022, developed a novel approach
- 1:20Speaker 2: called Abelx. This technology seems to tackle the glycan, mediated
- 1:25Speaker 2: suppression of the immune system head-on. True.
- 1:28Speaker 1: So, to break this down, abelks are these antibody lectin chimeras, right?
- 1:34Speaker 1: How do they work in practice?
- 1:36Speaker 2: Absolutely. They are designed to bind to specific cancer cells,
- 1:40Speaker 2: but more critically, they block the glycan interactions with immune-suppressive lectins.
- 1:46Speaker 2: This allows immune cells to recognize and attack the cancer
- 1:49Speaker 2: more effectively.
- 1:50Speaker 1: And in the lab, early tests showed promising results. human
- 1:54Speaker 1: immune cells were able to attack cancer cells more vigorously
- 1:58Speaker 1: when using these A-bulks, which is quite groundbreaking.
- 2:02Speaker 2: Yes, and preliminary tests in humanized mouse models suggested a
- 2:06Speaker 2: reduction in tumor burden. That's a significant step, but we
- 2:10Speaker 2: have to remember we are still in the lab phase.
- 2:14Speaker 2: No human trials have taken place yet.
- 2:16Speaker 1: That's true. So, what's the next step now? How do
- 2:21Speaker 1: we move from these promising lab results... to something we
- 2:24Speaker 1: can potentially apply in human patients.
- 2:26Speaker 2: Well, that's the million-dollar question. The next steps involve rigorous
- 2:32Speaker 2: testing to ensure the safety and efficacy of Abelix in
- 2:35Speaker 2: human subjects, and then, if everything checks out, moving into
- 2:40Speaker 2: clinical trials.
- 2:41Speaker 1: It's exciting to think about the potential, but there are
- 2:44Speaker 1: definitely some latent contradictions. Media reports sometimes oversimplify these advances.
- 2:50Speaker 1: implying that abulks are sweeping away the cancer sugar shield.
- 2:55Speaker 1: That's not quite accurate, right?
- 2:56Speaker 2: Exactly media often mischaracterizes the technology. Abulks don't remove glycan structures,
- 3:03Speaker 2: they block immune suppressive signals. This is a key distinction
- 3:07Speaker 2: to keep in mind.
- 3:08Speaker 1: And then there are the broader challenges. Even if all
- 3:11Speaker 1: goes well, the path to clinical application is long and
- 3:14Speaker 1: fraught with uncertainties. Side effects, for example, might arise from
- 3:19Speaker 1: prolonged use. and integrating Abelix with existing immunotherapies. Will that
- 3:24Speaker 1: create synergies or new issues?
- 3:26Speaker 2: Yes, and that's a critical debate angle. The modular design
- 3:30Speaker 2: of Abelix does open up new possibilities, but also raises
- 3:33Speaker 2: questions about their long-term viability and impact in clinical settings. Nonetheless,
- 3:39Speaker 2: it's definitely an innovative step that could fill gaps in
- 3:41Speaker 2: our current immunotherapy toolkit.
- 3:43Speaker 1: Let's dive into the specific mechanisms driving the success of Abelix.
- 3:50Speaker 1: it's crucial to understand the role of glycan modifications on
- 3:54Speaker 1: cancer cells.
- 3:55Speaker 2: Absolutely, Rachel. The cancer cell's ability to modulate its glycan
- 4:00Speaker 2: profile is like pulling the rug out from under the
- 4:02Speaker 2: immune system. Specifically, high levels of sialic acid on the
- 4:07Speaker 2: cell surface are the key here. These sialic acids bind
- 4:11Speaker 2: to siglec receptors, effectively dampening the inflammatory response.
- 4:15Speaker 1: That's a great point, Thomas. So … Can you elaborate
- 4:19Speaker 1: on the structure of abelks and how they interact with
- 4:21Speaker 1: these siglec receptors in a way that's different from traditional
- 4:25Speaker 1: glycan-based therapies?
- 4:27Speaker 2: Sure. Abelks are these innovative antibody lectin chimeris. The targeting
- 4:32Speaker 2: antibody part of the abelk binds to the cancer cell,
- 4:35Speaker 2: while the lectin decoy receptor part blocks the sialic acids
- 4:38Speaker 2: from binding to siglec receptors. This interaction essentially prevents the
- 4:43Speaker 2: molecular breaks on immune cells, allowing them to attack the cancer.
- 4:47Speaker 1: It's like the lectin part is a decoy that tricks
- 4:50Speaker 1: the Siglec receptors, right? How does this modular design affect
- 4:55Speaker 1: its potential in clinical settings?
- 4:57Speaker 2: Exactly, Rachel. This modular design means Abelks can be tailored
- 5:01Speaker 2: to target multiple glycosylation pathways, which is a key advantage.
- 5:06Speaker 2: But it also brings up the question of how well
- 5:08Speaker 2: these therapies will integrate with existing immunotherapies. Will they work
- 5:12Speaker 2: better or just differently?
- 5:13Speaker 1: The collaboration between Carolyn Bertozzi and Jessica Stark at Stanford
- 5:17Speaker 1: and MIT really highlights this. Their work at Stanford, paired
- 5:21Speaker 1: with Valora Therapeutics, co-founded by Stark, brings a lot of
- 5:25Speaker 1: technical expertise. Tell me more about their contributions.
- 5:29Speaker 2: Bertozzi is a big name in this field. She is
- 5:32Speaker 2: pioneering glycoimmunochemistry and bioorthogonal chemistry. Stark's work focuses on translating
- 5:39Speaker 2: these innovations into practical therapies. Their collaboration is crucial, especially
- 5:45Speaker 2: given the complexity of developing Abelks.
- 5:47Speaker 1: It's fascinating how these researchers are pushing the boundaries. But
- 5:51Speaker 1: let's not forget, there are still questions about the safety
- 5:55Speaker 1: and long-term efficacy of Abelks. How are these being addressed?
- 6:00Speaker 2: That's a valid concern. Right now, the most promising data
- 6:04Speaker 2: comes from humanized mouse models, which showed reduced tumor burden. However...
- 6:09Speaker 2: to really understand potential side effects and long-term impacts, we
- 6:13Speaker 2: need to see how these therapies fare in human clinical trials.
- 6:17Speaker 1: Right, and the data from these preliminary mouse models is
- 6:20Speaker 1: certainly encouraging, but it's a big leap to human subjects.
- 6:24Speaker 1: What steps are being taken to ensure safety?
- 6:27Speaker 2: The modular design itself is a step towards mitigating risks.
- 6:31Speaker 2: By targeting multiple glycosylation pathways, it reduces the chance of
- 6:36Speaker 2: adverse effects from a single mechanism. However, clinical trials will
- 6:41Speaker 2: be critical to fully assess the safety profile.
- 6:44Speaker 1: And speaking of which, how do Abelbooks fit into the
- 6:47Speaker 1: broader landscape of cancer immunotherapy? They seem like a complementary
- 6:52Speaker 1: therapy rather than a replacement.
- 6:54Speaker 2: Definitely. The potential for Abelbooks to enhance the immune system's
- 6:58Speaker 2: ability to recognize and attack cancer cells while working alongside
- 7:02Speaker 2: other therapies is exciting. This could open up new synergies
- 7:06Speaker 2: that could benefit patients with limited options.
- 7:08Speaker 1: Considering all the buzz about Abelgas, it's clear that media
- 7:12Speaker 1: portrayal might have oversimplified things. What we have seen so
- 7:17Speaker 1: far is just the tip of the iceberg.
- 7:19Speaker 2: Absolutely, Rachel. Media often uses slogans to make complex science accessible,
- 7:25Speaker 2: but it can lead to misunderstandings. For example, saying Abelx
- 7:29Speaker 2: removed the cancer sugar shield isn't entirely accurate. What Abelks
- 7:34Speaker 2: do is block immune-suppressive interactions rather than modifying glycans themselves.
- 7:39Speaker 1: That's a crucial distinction. And we can't take the safety
- 7:43Speaker 1: and efficacy claims at face value either. Since there is
- 7:47Speaker 1: no clinical trial data in humans, we are flying somewhat blind.
- 7:52Speaker 2: Exactly. Right now, all we have are promising results from
- 7:56Speaker 2: in vitro and in vivo experiments. But translating those results
- 8:00Speaker 2: to the complex human body is a whole different ballgame.
- 8:04Speaker 2: We need to consider the safety profile more deeply.
- 8:07Speaker 1: Let's talk safety then. One concern is the potential for
- 8:10Speaker 1: off-target effects. A-bulks target the immune system, so we could
- 8:15Speaker 1: see unintended interactions that might suppress normal immune function.
- 8:19Speaker 2: That's a valid point. Another issue is the modularity of
- 8:23Speaker 2: the approach. While it allows for targeting multiple pathways, We
- 8:27Speaker 2: also need to ensure that this doesn't open the door
- 8:29Speaker 2: to overcomplicating treatment regimens, which could be a logistical nightmare
- 8:34Speaker 2: in clinical settings.
- 8:35Speaker 1: Right. And that's the crucial nuance here. The modularity can
- 8:39Speaker 1: be a blessing but also a curse. It's vital we
- 8:43Speaker 1: don't lose sight of the simplicity needed in clinical applications.
- 8:47Speaker 1: Overly complex therapies could lead to poor adherence and compliance issues.
- 8:52Speaker 2: Exactly, which brings up an interesting contradiction. On one hand,
- 8:57Speaker 2: the ability to target multiple glycosylation pathways is exciting. On
- 9:02Speaker 2: the other, ensuring consistent and safe delivery of these therapies
- 9:06Speaker 2: in the context of real-world patient care is a tall order.
- 9:09Speaker 1: Speaking of which, how do you see the integration of
- 9:12Speaker 1: Abelbooks with existing immunotherapies playing out? Are there potential synergies
- 9:18Speaker 1: or just more complexity?
- 9:20Speaker 2: The hope is that they could enhance existing treatments. For instance,
- 9:24Speaker 2: A-bulks might amplify the effects of checkpoint inhibitors, but the
- 9:28Speaker 2: devil is in the details. We need to carefully gauge
- 9:32Speaker 2: whether the benefits outweigh the added complexity of combining therapies.
- 9:36Speaker 1: And finally, what role do you think the ongoing research
- 9:39Speaker 1: will play in shaping our understanding of these therapies? How
- 9:44Speaker 1: will it influence clinical guidelines and patient outcomes?
- 9:48Speaker 2: Precisely. Clinical trials will be pivotal here. They will not
- 9:52Speaker 2: only test the safety and efficacy of Abelks, but also
- 9:55Speaker 2: refine our understanding of how these therapies interact with the
- 9:59Speaker 2: immune system. This will be crucial for updating guidelines and
- 10:03Speaker 2: ensuring that when Abelks are integrated into practice, they are
- 10:07Speaker 2: used in the most optimal way possible.
- 10:09Speaker 1: That's a deep and multifaceted issue. It's clear that Abelks
- 10:13Speaker 1: hold a lot of promise, but Therese still a long
- 10:16Speaker 1: road to travel before we see them widely adopted in
- 10:20Speaker 1: clinical settings. So, moving forward, Jessica Stark mentioned that the
- 10:24Speaker 1: modular design of Abelks allows for targeting multiple glycosylation pathways.
- 10:30Speaker 1: This suggests a high degree of flexibility, but how does
- 10:33Speaker 1: that translate into practical applications in real-world settings?
- 10:37Speaker 2: Right, and that's the crucial nuance here. While the concept
- 10:40Speaker 2: is exciting, the devil is always in the details. For instance,
- 10:45Speaker 2: the modular design might work well in the lab, where
- 10:48Speaker 2: you can easily tweak the components, but in clinical trials,
- 10:51Speaker 2: patients don't get to have their cancer cells genetically modified.
- 10:55Speaker 2: The real-world implementation could face significant logistical and practical hurdles.
- 11:01Speaker 1: Exactly, which brings up an interesting contradiction. The media often
- 11:06Speaker 1: portrays these therapies as a silver bullet, but the nuances
- 11:10Speaker 1: you are highlighting show that they are not as straightforward
- 11:13Speaker 1: as that. This modular design also means you might need
- 11:17Speaker 1: to customize the treatment for each patient, which could drive
- 11:21Speaker 1: up costs and complexity.
- 11:22Speaker 2: That's wild when you look at the raw numbers. It
- 11:25Speaker 2: could be a double-edged sword. Customized treatments are indeed more precise,
- 11:30Speaker 2: but they also mean a longer, more intensive treatment process.
- 11:34Speaker 2: We are back to the old debate, is it worth
- 11:36Speaker 2: the cost?
- 11:37Speaker 1: True, and it raises the question of how these personalized
- 11:41Speaker 1: treatments will be integrated into the healthcare ecosystem. Will they
- 11:45Speaker 1: become standard of care, or will they remain niche treatments
- 11:49Speaker 1: for specific cases? It's a big ask for the healthcare
- 11:52Speaker 1: system to handle personalized medicine at such a scale.
- 11:56Speaker 2: Exactly, and that brings us to the clinical translation question.
- 12:01Speaker 2: As Jessica Stark pointed out, the modular design of Abelix
- 12:04Speaker 2: is promising, but the real test will be in the
- 12:07Speaker 2: clinical trials. Do these therapies work as well as they
- 12:10Speaker 2: do in the lab? What kind of side effects might
- 12:13Speaker 2: they have? and how will they interact with existing treatments?
- 12:16Speaker 1: Speaking of clinical trials, what do we know about the
- 12:19Speaker 1: potential side effects of Abelks? The modular design might allow
- 12:23Speaker 1: for customization, but can we really predict all possible outcomes?
- 12:28Speaker 1: Is the data sufficient to support their use in human trials?
- 12:31Speaker 1: Or are there still many unknowns?
- 12:33Speaker 2: Great question. The preliminary results are promising, but recall that
- 12:38Speaker 2: Therese no human data yet. In the mouse models, there
- 12:41Speaker 2: was a reduction in tumor burden. But it's a long
- 12:44Speaker 2: way from there to a clinic. We need to know
- 12:46Speaker 2: more about the long-term effects, both positive and negative.
- 12:50Speaker 1: And this ties back to the integration challenge. How will
- 12:53Speaker 1: Abelks fare when combined with existing immunotherapies? Do we have
- 12:58Speaker 1: enough data to suggest they will work synergistically? Or could
- 13:02Speaker 1: they potentially interfere with each other?
- 13:04Speaker 2: Right. The potential synergy with existing therapies is exciting, but
- 13:09Speaker 2: it also introduces another layer of complexity. we need to
- 13:12Speaker 2: ensure that Abelk's want undermine the effectiveness of other treatments.
- 13:16Speaker 2: The interplay between these therapies is critical for their success.
- 13:20Speaker 1: And this, in turn, highlights the ongoing nature of research
- 13:24Speaker 1: in this field. Therese so much to explore and understand.
- 13:29Speaker 1: It's a marathon, not a sprint.
- 13:31Speaker 2: Absolutely. The future of cancer immunotherapy is shaped by ongoing
- 13:36Speaker 2: research and development. But for now, the key will be
- 13:40Speaker 2: moving from these initial promising findings to concrete clinical trials
- 13:44Speaker 2: and eventually widespread application.
- 13:47Speaker 1: So, as we wrap up today, I think it's important
- 13:50Speaker 1: to emphasize how groundbreaking this research is, not just in
- 13:54Speaker 1: the lab, but in terms of its potential impact on
- 13:57Speaker 1: real patients. Absolutely.
- 13:59Speaker 2: The ability to modulate cancer cells' glycan profiles via A-bulks
- 14:04Speaker 2: really could reshape our approach to immunotherapy. It's like adding
- 14:08Speaker 2: another key piece to the puzzle.
- 14:09Speaker 1: Exactly. And given that the current immunotherapies focus so heavily
- 14:14Speaker 1: on specific antigens, the modularity of Abelglux is a big deal.
- 14:19Speaker 1: They can target multiple glycosylation pathways simultaneously. Right?
- 14:24Speaker 2: That's right. It's akin to having a chisel rather than
- 14:28Speaker 2: a scalpel. Carolyn Bertassi's approach can carve away different parts
- 14:32Speaker 2: of the sugar shield, not just one. This is crucial
- 14:36Speaker 2: because cancer cells often have a dynamic glycan profile, which
- 14:40Speaker 2: can make targeted therapies less effective over time.
- 14:43Speaker 1: And this flexibility could also mean fewer side effects, because
- 14:47Speaker 1: the abelks are hitting the immune-suppressive molecules directly, rather than
- 14:51Speaker 1: trying to alter the cancer cells themselves. That's a pretty
- 14:55Speaker 1: smart design, if you ask me.
- 14:57Speaker 2: Definitely. But it's important to note that we are still
- 15:01Speaker 2: in the early stages of testing. While the mice showed
- 15:04Speaker 2: promising reductions in tumor burden, the next step is to
- 15:08Speaker 2: see how human immune systems will respond. The safety and
- 15:11Speaker 2: efficacy in larger populations are still a big unknown.
- 15:15Speaker 1: True, and moving from lab tests to human trials is
- 15:19Speaker 1: a big leap. There's a lot that can go wrong,
- 15:23Speaker 1: but on the bright side, this is also where the
- 15:25Speaker 1: real innovation happens. It's where the ideas can become part
- 15:30Speaker 1: of everyday care.
- 15:31Speaker 2: Right. I think another key aspect is the potential for
- 15:34Speaker 2: combining Abelks with existing immunotherapies. Jessica Stark mentioned that their
- 15:40Speaker 2: modular design could complement current treatments, not replace them. This
- 15:44Speaker 2: could be a win-win if it works out.
- 15:46Speaker 1: Exactly. So, while we are cautiously optimistic, Therese still a
- 15:51Speaker 1: lot of work to do. What do you think the
- 15:54Speaker 1: next steps should be?
- 15:55Speaker 2: First, more comprehensive clinical trials in various stages to test
- 15:59Speaker 2: for safety and efficacy. Then, exploring different clinical scenarios to
- 16:04Speaker 2: see where Abelks fit best, and of course refining the
- 16:07Speaker 2: design based on feedback from early trials.
- 16:10Speaker 1: And all this while keeping an eye on potential challenges,
- 16:14Speaker 1: like long-term safety concerns or unintended side effects. It's a
- 16:19Speaker 1: delicate balance.
- 16:20Speaker 2: For sure. But with Carolyn Bertossi leading the way, I
- 16:23Speaker 2: am confident we will continue to make progress. and the
- 16:26Speaker 2: potential benefits for cancer patients could be truly transformative.
- 16:30Speaker 1: That brings us to the end of today's episode. Thank
- 16:33Speaker 1: you so much for spending part of your day with me.
- 16:36Speaker 1: If you found this episode's tips helpful and want to
- 16:38Speaker 1: make sure you don't miss the next conversation, please take
- 16:41Speaker 1: a quick second to hit that subscribe or follow button
- 16:44Speaker 1: on whatever platform you are listening on. It's a completely
- 16:47Speaker 1: free way to support the show and helps more people
- 16:50Speaker 1: find us. This podcast is independently produced. So if you
- 16:54Speaker 1: are ever in a position where you would like to
- 16:56Speaker 1: help keep it running, we do accept small donations. You
- 16:59Speaker 1: can find a link right in the episode description below
- 17:02Speaker 1: to buy us a coffee or contribute what you can.
- 17:05Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 17:09Speaker 1: and we will talk again soon.